OXIGON®
OXIGON® is a clinical stage drug candidate being developed by the company as a promising potential disease-modifying drug for Alzheimer's disease based on its unique combination of pharmacological properties. The drug has the potential to protect the brain and other tissues against oxidative stress and in addition appears to stabilize the less toxic soluble forms of beta-amyloid preventing aggregation into more toxic forms.

OXIGON has been successfully tested for safety across animal species and in two human Phase I clinical trials conducted in a total of 90 healthy elderly volunteers. The company is planning to initiate clinical trials in Alzheimer's disease patients to test various doses of the drug to examine its effects on various relevant biological markers that are measurable in blood and cerebrospinal fluid. In addition, patients will be tested for using a variety of cognitive measures.

Additional studies are being conducted to explore the drugs potential utility to treat other diseases such as Parkinson's disease, Huntington's disease, motor neuron disease, Glaucoma, cardiovascular disease, Friedrich ataxia, and protection against radiation injury.

IN-N01
IN-N01 is a humanized monoclonal antibody based on the Company's ANTISENILIN® monoclonal antibody technology. It is designed to specifically block the neurotoxicity of beta amyloid in the brains of Alzheimer's patients while minimizing the potential for adverse effects. IN-N01 is being developed as a second generation drug candidate with the aim of improving the overall safety and efficacy compared to other drug candidates in more advanced development.

RECALL-VAX™
Aβ vaccines represent a promising approach to develop disease-modifying agents for Alzheimer's disease, with potential not only to treat the disease but also to prevent its onset.

Aβ vaccines act by stimulating the immune system to produce antibodies that clear beta-amyloid peptides (Aβ) and prevent its further accumulation and deposition. Studies in animal models of Alzheimer's disease, as well as clinical studies, have shown that active immunization can result in clearance of amyloid plaques, prevent accumulation of Aβ, and arrest cognitive decline.

Intellect's active immunization technology, RECALL-VAX™, is focused on the development of chimeric peptide vaccines of very short, free-end fragments of Aβ linked to a well-characterized T-helper cell epitope, such as tetanus toxoid, against which most people have been vaccinated, which can elicit a memory response. These types of T-helper cell epitopes are particularly suitable for vaccines aimed at elderly populations because the memory response that they elicit facilitates activation of a senescent immune system.